Welcome to Movers & Shakers, a roundup of the latest executive movements in the healthcare space.
Johnson & Johnson names new EVP, pharmaceuticals, R&D
John Reed, MD, PhD, has been named executive vice president of pharmaceuticals at Johnson & Johnson. Reed has more than 35 years of experience in biomedical research and previously served as executive vice president, global head of research and development for Sanofi.
Prior to Sanofi, Reed served as global head of pharmaceutical research & early development at Roche. In addition, Reed is one of the world’s most highly cited physician-scientists, and has authored more than 900 research publications and received more than 130 patents. According to the announcement about his new role, Reed was among the top 10 most cited researchers in life sciences and medicine for a decade. He is still among the top 100 most cited scientists.
Reed will join Johnson & Johnson April 3, succeeding William Hait, MD, PhD, who has served as interim head of Johnson & Johnson’s Pharmaceutical R&D organization since August 2022.
“Dr. Reed is an accomplished leader and highly regarded researcher with an extraordinary track record for discovering and developing life-saving innovations on a global scale,” Joaquin Duato, chairman of the board andCEO of Johnson & Johnson, said in a statement. “I am confident his experience and leadership will enable our Pharmaceutical R&D organization to continue to accelerate innovation and competitiveness, invest with focus and discipline and improve the lives of the patients we serve around the world with transformational medicines.”
Community Healthcare Trust CEO takes medical leave
The CEO of Community Healthcare Trust, Timothy Wallace, who also serves as chairman and president, has taken a medical leave of absence, the company announced.
Community Healthcare Trust is a healthcare real estate investment trust (REIT) headquartered in Tennessee. The company’s portfolio includes 174 properties spanning 34 states, including medical office buildings, acute inpatient behavioral facilities, inpatient rehab facilities, physician clinics, specialty centers and more.
David Dupuy, executive vice president and chief financial officer, will serve as interim CEO while Wallace is on leave, which is due to complications from a peptic ulcer. Wallace has served as CEO since the REIT was founded in 2014.
Emids announces CEO, chairman positions
Emids, digital transformation solutions provider in the healthcare and life sciences sector, has named Sean Narayanan as its CEO and a member of the board of directors. Saurabh Sinha, currently CEO and founder of the company, will transition to the role of chairman of the board.
Narayanan comes to Emids after leading digital services firm Apexon for two years. Prior to Apexon, he served as senior executive vice president and CEO of the $5 billion business and platform solutions division of Atos. He has also previously held executive roles at Liquidhub, iGate (now Capgemini) and Cognizant.
Emids, which was founded in Nashville in 1999, offers technology-led digital transformation, data and AI, and consulting services. The company has a global headcount of more than 3,300 team members, with a recent bump in client adoption over the last two years for its proprietary data management platform CoreLAKE and rapid health innovation platform MHC. Emids also hosts an annual healthcare industry conference, The Emids Healthcare Summit.
Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."